Why it may matterVerify against the original reporting
The company posted a positive swing in profitability metrics (Adjusted EBITDA) and improving gross margins (51.1%), along with revenue growth and leadership additions. These factors support a more favorable near-term view, especially if Greenbrook continues to scale and cash burn remains on a downward trend. Historically, similar quarterly improvements in margin and cash flow for small-cap healthcare tech names have driven short- to medium-term upside, barring reversals in reimbursement dynamics or slower-than-expected clinic growth.
AI summary
What happened, with direct paths to the underlying reporting
Neuronetics reported Q2 2026 revenue of $41.6 million, up 9.1% YoY, with Greenbrook revenue at $26.9 million, up 16.8%. Adjusted EBITDA turned positive to $0.3 million, while net loss narrowed to $3.4 million. The company reaffirmed 2026 guidance and highlighted leadership changes and a stronger go-to-market, signaling progress toward profitability and reduced cash burn in the second half.
Q2 2026 revenue was $41.6M, up 9.1% YoY.
Greenbrook revenue was $26.9M, up 16.8% YoY.
Adjusted EBITDA turned positive at $0.3M; net loss $3.4M vs $10.1M prior.
Leadership changes: Nir Naor named CFO; Cory Anderson; Rob Greene in Sales.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Neuronetics' Greenbrook TMS acquisition transforms it into a vertically integrated mental-health platform, adding TMS and Spravato. The Q1 beat and BTIG's Buy rating with a $5 tar…
Neuronetics to acquire Greenbrook in all-stock deal to enhance NeuroStar's reach. Merger expected to boost revenue growth and deliver $15 million in annual cost savings. Global me…
